Portola’s Blood Thinner Betrixaban Flops in Phase 3

Portola Pharmaceuticals’ long-lasting Faxtor Xa inhibitor betrixaban missed its primary endpoint in a Phase 3 trial for preventing blood clots.

The APEX trial compared oral betrixaban to standard of care preventive anticoagulation with injectable enoxaparin in acute medically ill patients at risk of proximal deep venous thrombosis or nonfatal pulmonary embolism. APEX enrolled 7,513 patients at more than 450 clinical sites worldwide.